Opdivo Qvantig in Sri Lanka

Opdivo Qvantig - overview

Opdivo Qvantig (nivolumab) is manufactured by Bristol Myers Squibb and indicated for approved across most solid tumor indications for which IV nivolumab is approved, see full prescribing information. It is a subcutaneous PD-1 inhibitor co-formulated with hyaluronidase approved by the US FDA in 2024 and may be accessible to patients in Sri Lanka through a Named Patient Program or personal-import pathway.

Access in Sri Lanka

Sri Lanka's NMRA permits named-patient import for rare-disease specialty drugs via physician request.

How Reserve Meds coordinates access in Sri Lanka

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Sri Lanka-specific eligibility.
3. Treating physician in Sri Lanka issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Opdivo Qvantig from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Sri Lanka.

Typical timeline for Sri Lanka

End-to-end, most requests are completed in 2-6 weeks. Sri Lanka's tier 3 regulatory maturity typically supports longer processing times.

What patients and physicians in Sri Lanka ask

• Is the pathway legal in Sri Lanka? Yes - it operates under Sri Lanka's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Sri Lanka able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Opdivo Qvantig in Sri Lanka

Request Opdivo Qvantig